INmune Bio, Inc.

INMB Healthcare Biotechnology

INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024. In the quarter to June 2026, revenue grew 8.70%, EPS grew 95.2% and free cash flow grew 55.4%, each against the same quarter a year earlier.

1.57 0.08 −4.85%
Market cap
$45.8M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
4/9
Altman Z
−10.46
Beneish M
−3.67
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
4.04 4.24 3.55 4.17
Net Debt/EBITDA
13.06 3.71 4.57 3.73
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.13) (0.13) (0.12) (0.21)
Book value per Share
0.76 0.74 0.95 0.95
Free Cash Flow
(3.60) (3.40) (3.09) (5.63)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates